Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Antipsychotic Paliperidone ER Moves Into Phase III

Executive Summary

Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies

You may also be interested in...



Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone

J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection

J&J submits Risperdal follow-on

Johnson & Johnson submits NDA for paliperidone extended-release Nov. 29, giving the schizophrenia therapy a user fee date in late September 2006. The timeline puts J&J on track to launch paliperidone ER in advance of generic competition to Risperdal (risperidone), which could lose exclusivity as early as mid-2008. The agent is a metabolite of risperidone and uses J&J's proprietary OROS controlled-release technology, gained through the company's acquisition of Alza in 1999 (1"The Pink Sheet" April 19, 2004, p. 12)...

Related Content

UsernamePublicRestriction

Register

PS043771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel